Evidence mapPaperPMID 39594552Full record

ArticleAntioxidants (Basel, Switzerland)2024

Nitroxyl Hybrids with Curcumin and Stilbene Scaffolds Display Potent Antioxidant Activity, Remodel the Amyloid Beta Oligomer, and Reverse Amyloid Beta-Induced Cytotoxicity.

Madhu S Budamagunta, Hidetoshi Mori, Joshua Silk, Ryan R Slez, Balázs Bognár, Ulises Ruiz Mendiola, Tamás Kálai, Izumi Maezawa, John C Voss

Abstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Madhu S BudamaguntaDepartment of Biochemistry & Molecular Medicine, University of California, Davis, CA 95616, USA.
Hidetoshi MoriCenter for Genomic Pathology, University of California Davis, Sacramento, CA 95817, USA.
Joshua SilkDepartment of Biochemistry & Molecular Medicine, University of California, Davis, CA 95616, USA.
Ryan R SlezDepartment of Biochemistry & Molecular Medicine, University of California, Davis, CA 95616, USA.
Balázs BognárInstitute of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Pécs, Honvéd St. 1., H-7624 Pécs, Hungary.ORCID 0000-0001-6695-6839
Ulises Ruiz MendiolaM.I.N.D. Institute and Department of Pathology and Laboratory Medicine, University of California Davis, Sacramento, CA 95817, USA.ORCID 0000-0002-7429-3614
Tamás KálaiInstitute of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Pécs, Honvéd St. 1., H-7624 Pécs, Hungary.
Izumi MaezawaM.I.N.D. Institute and Department of Pathology and Laboratory Medicine, University of California Davis, Sacramento, CA 95817, USA.
John C VossDepartment of Biochemistry & Molecular Medicine, University of California, Davis, CA 95616, USA.ORCID 0000-0001-9279-209X

Funding

UC DAVIS ALZHEIMERS DISEASE CENTER COREP30AG010129 · UNIVERSITY OF CALIFORNIA DAVIS · 1991 to 2005
$7.1M
Soluble epoxide hydrolase-regulated lipid signaling in Alzheimer’s diseaseR01AG071665 · UNIVERSITY OF CALIFORNIA AT DAVIS · 2025 to 2025
$624k
National Research, Development, and Innovation Fund of Hungary NKFI K 137793NIA NIH HHS P30 AG010129NIA NIH HHS R01 AG071665NIA NIH HHS RF1 AG071665NIH HHS P30 AG010129NIH HHS RF1 AG071665
6 · The paper itself

Abstract

The disorder and heterogeneity of low-molecular-weight amyloid-beta oligomers (AβOs) underlie their participation in multiple modes of cellular dysfunction associated with the etiology of Alzheimer's disease (AD). The lack of specified conformational states in these species complicates efforts to select or design small molecules to targeting discrete pathogenic states. Furthermore, targeting AβOs alone may be therapeutically insufficient, as AD progresses as a multifactorial, self-amplifying cascade. To address these challenges, we have screened the activity of seven new candidates that serve as Paramagnetic Amyloid Ligand (PAL) candidates. PALs are bifunctional small molecules that both remodel the AβO structure and localize a potent antioxidant that mimics the activity of SOD within live cells. The candidates are built from either a stilbene or curcumin scaffold with nitroxyl moiety to serve as catalytic antioxidants. Measurements of PAL AβO binding and remolding along with assessments of bioactivity allow for the extraction of useful SAR information from screening data. One candidate (HO-4450; PMT-307), with a six-membered nitroxyl ring attached to a stilbene ring, displays the highest potency in protecting against cell-derived Aβ. A preliminary low-dose evaluation in AD model mice provides evidence of modest treatment effects by HO-4450. The results for the curcumin PALs demonstrate that the retention of the native curcumin phenolic groups is advantageous to the design of the hybrid PAL candidates. Finally, the PAL remodeling of AβO secondary structures shows a reasonable correlation between a candidate's bioactivity and its ability to reduce the fraction of antiparallel β-strand.

Indexed as

Alzheimer’s diseaseamyloid beta peptideantioxidantAβ oligomerbifunctional drugelectron paramagnetic resonance spectroscopyEPRnitroxideoxidative stressprotein misfolding

Identifiers

PMID39594552
PMCPMC11591036

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.